This is an aggregated industry headline. Read the full story at FierceBiotech →
How iBio aims to stand out in obesity by targeting 'both sides of the equation' for antibody discovery
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery platform it picked up in 2022.
By FierceBiotech
· Jun 26, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
BeOne Medicines has extended its relationship with Blood Cancer United, committing $5 million over three years…
The WeekBriefing
Otsuka’s ADHD drug candidate met its Phase 3b endpoint in adults with comorbid anxiety, adding key data weeks …
The WeekSTAT News ↗
A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary h…